Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Summary
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.
Official title: A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-12-30
Completion Date
2026-05
Last Updated
2026-04-07
Healthy Volunteers
Yes
Conditions
Interventions
HRS-6257
HRS-6257
placebo
placebo
Locations (1)
Third Xiangya Hospital of Central South University
Changsha, Hunan, China